What are the limitations of the BWH High Risk SCC Staging?

While the BWH High Risk SCC Staging is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the BWH High Risk SCC Staging to ensure safe bedside use and optimal diagnostic accuracy.

How does the BWH High Risk SCC Staging compare to other Dermatology scores?

The BWH High Risk SCC Staging is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the BWH High Risk SCC Staging free to use?

Yes. OpiCalc provides the BWH High Risk SCC Staging completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

SCORAD

SCORAD Index: Unified assessment of Atopic Dermatitis severity (Area, Intensity, Symptoms).

Affected Area (A) — (%)

0%0%100%

Intensity Factors (B) — (0-3)

erythema

edema

crusting

excoriation

lichenification

dryness

Itching (C)

0010

Sleep Loss (C)

0010

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Evaluating the severity of atopic dermatitis (eczema) objectively.
Monitoring disease progression and treatment response over time.
Standardized reporting in clinical trials for atopic dermatitis therapies.

CLINICAL INSIGHT

How it Works

Formula

Variables

A: Extent of disease as percentage of Body Surface Area (BSA) affected (0-100).
B: Intensity of 6 specific morphologic lesions (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, and dryness/xerosis) graded 0-3. Max 18.
C: Subjective symptoms (pruritus and sleep loss) over the last 3 days, graded 0-10 on VAS. Max 20.

CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

Dryness (xerosis) is evaluated ONLY on uninvolved skin areas.
It combines both objective physician assessment and subjective patient-reported outcomes, making it very comprehensive.
A score > 50 indicates severe atopic dermatitis.

CLINICAL INSIGHT

Next Steps

Interpretation

< 25: Mild disease.
25 - 50: Moderate disease.
> 50: Severe disease. Consider escalation to systemic immunosuppression or biologics.

SCORAD

SCORAD Index: Unified assessment of Atopic Dermatitis severity (Area, Intensity, Symptoms).

Affected Area (A) — (%)

0%0%100%

Intensity Factors (B) — (0-3)

erythema

edema

crusting

excoriation

lichenification

dryness

Itching (C)

0010

Sleep Loss (C)

0010

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Evaluating the severity of atopic dermatitis (eczema) objectively.
Monitoring disease progression and treatment response over time.
Standardized reporting in clinical trials for atopic dermatitis therapies.

CLINICAL INSIGHT

How it Works

Formula

Variables

A: Extent of disease as percentage of Body Surface Area (BSA) affected (0-100).
B: Intensity of 6 specific morphologic lesions (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, and dryness/xerosis) graded 0-3. Max 18.
C: Subjective symptoms (pruritus and sleep loss) over the last 3 days, graded 0-10 on VAS. Max 20.

CLINICAL INSIGHT

Practical Pearls

Clinical Pearls

Dryness (xerosis) is evaluated ONLY on uninvolved skin areas.
It combines both objective physician assessment and subjective patient-reported outcomes, making it very comprehensive.
A score > 50 indicates severe atopic dermatitis.

CLINICAL INSIGHT

Next Steps

Interpretation

< 25: Mild disease.
25 - 50: Moderate disease.
> 50: Severe disease. Consider escalation to systemic immunosuppression or biologics.